Tags

Type your tag names separated by a space and hit enter

Levamisole can reduce the high serum tumour necrosis factor-alpha level to a normal level in patients with erosive oral lichen planus.
Clin Exp Dermatol. 2007 May; 32(3):308-10.CE

Abstract

In this study, we measured the baseline serum levels of tumour necrosis factor (TNF)-alpha in 158 patients with oral lichen planus (OLP) and in 54 normal control subjects. In total, 60 patients with erosive OLP (EOLP) with relatively high TNF-alpha levels were treated with levamisole and the serum TNF-alpha levels measured after treatment. We found that the mean +/- SD serum level of TNF-alpha in patients with either type of EOLP (12.0 +/- 1.7 pg/mL, P<0.005), major EOLP (15.5 +/- 4.4 pg/mL, P<0.001), minor EOLP (11.1 +/- 1.8 pg/mL, P<0.01), or nonerosive OLP (6.1 +/- 1.7 pg/mL, P<0.05) was significantly higher than that (3.8 +/- 0.2 pg/mL) of normal control subjects. Treatment with levamisole for a period of 0.5-7.5 months significantly reduced the mean serum TNF-alpha level from 22.6 +/- 3.4 pg/mL to 6.2 +/- 0.8 pg/mL (P<0.001) in 60 patients with EOLP. We conclude that levamisole can reduce high serum TNF-alpha levels to normal in patients with EOLP.

Authors+Show Affiliations

School of Dentistry, College of Medicine, National Taiwan University, Taipei, Taiwan.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17397355

Citation

Sun, A, et al. "Levamisole Can Reduce the High Serum Tumour Necrosis Factor-alpha Level to a Normal Level in Patients With Erosive Oral Lichen Planus." Clinical and Experimental Dermatology, vol. 32, no. 3, 2007, pp. 308-10.
Sun A, Chia JS, Wang JT, et al. Levamisole can reduce the high serum tumour necrosis factor-alpha level to a normal level in patients with erosive oral lichen planus. Clin Exp Dermatol. 2007;32(3):308-10.
Sun, A., Chia, J. S., Wang, J. T., & Chiang, C. P. (2007). Levamisole can reduce the high serum tumour necrosis factor-alpha level to a normal level in patients with erosive oral lichen planus. Clinical and Experimental Dermatology, 32(3), 308-10.
Sun A, et al. Levamisole Can Reduce the High Serum Tumour Necrosis Factor-alpha Level to a Normal Level in Patients With Erosive Oral Lichen Planus. Clin Exp Dermatol. 2007;32(3):308-10. PubMed PMID: 17397355.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Levamisole can reduce the high serum tumour necrosis factor-alpha level to a normal level in patients with erosive oral lichen planus. AU - Sun,A, AU - Chia,J S, AU - Wang,J T, AU - Chiang,C P, PY - 2007/4/3/pubmed PY - 2007/8/22/medline PY - 2007/4/3/entrez SP - 308 EP - 10 JF - Clinical and experimental dermatology JO - Clin Exp Dermatol VL - 32 IS - 3 N2 - In this study, we measured the baseline serum levels of tumour necrosis factor (TNF)-alpha in 158 patients with oral lichen planus (OLP) and in 54 normal control subjects. In total, 60 patients with erosive OLP (EOLP) with relatively high TNF-alpha levels were treated with levamisole and the serum TNF-alpha levels measured after treatment. We found that the mean +/- SD serum level of TNF-alpha in patients with either type of EOLP (12.0 +/- 1.7 pg/mL, P<0.005), major EOLP (15.5 +/- 4.4 pg/mL, P<0.001), minor EOLP (11.1 +/- 1.8 pg/mL, P<0.01), or nonerosive OLP (6.1 +/- 1.7 pg/mL, P<0.05) was significantly higher than that (3.8 +/- 0.2 pg/mL) of normal control subjects. Treatment with levamisole for a period of 0.5-7.5 months significantly reduced the mean serum TNF-alpha level from 22.6 +/- 3.4 pg/mL to 6.2 +/- 0.8 pg/mL (P<0.001) in 60 patients with EOLP. We conclude that levamisole can reduce high serum TNF-alpha levels to normal in patients with EOLP. SN - 0307-6938 UR - https://www.unboundmedicine.com/medline/citation/17397355/Levamisole_can_reduce_the_high_serum_tumour_necrosis_factor_alpha_level_to_a_normal_level_in_patients_with_erosive_oral_lichen_planus_ DB - PRIME DP - Unbound Medicine ER -